Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel 4-Antigen Vaccine (SA4Ag).


causes serious health care- and community-associated disease, requiring improved preventive measures such as vaccines. The investigational 4-antigen vaccine (SA4Ag), comprising capsular polysaccharide serotypes 5 and 8 (CP5 and CP8) conjugated to CRM, recombinant mutant clumping factor A (rClfA), and recombinant manganese transporter protein C (rP305A or rMntC), was well tolerated, inducing robust functional immune responses to all 4 antigens through 12 months postvaccination. This is a serological extension study through 36 months postvaccination.